CUSTOM DERMATOLOGY SEARCH:
Safety, Efficacy & Recurrence Rates of Imiquimod Cream 5% for Treatment of Anogenital Warts
M.L. Diamantis, BS1; B.L. Bartlett, MD2; S.K. Tyring, MD, PhD3
Imiquimod is an immune response modifier that was approved by the US FDA in 1997 for the topical treatment of anogenital warts in individuals 12 years old and older. An estimated 30%-50% of sexually active adults in the US are infected with human papillomavirus (HPV), and approximately 1%-2% of this same population have clinically evident genital warts.1 This review will focus on studies that evaluate the safety, efficacy, and recurrence rates of imiquimod 5% cream in the treatment of anogenital warts in non-HIV-infected men and women. Local inflammatory reactions were the most frequent adverse effects, with local erythema being the most common. Overall, imiquimod 5% cream is a safe and efficacious treatment for anogenital warts.
Imiquimod cream is supplied in individual packets. Each gram of the 5% cream contains 50mg of imiquimod in an off-white oil-in-water vanishing cream base.2 The US Center for Disease Control recommends that imiquimod 5% cream be applied once daily at bedtime, 3 times per week for up to 16 weeks. The product should be washed off with mild soap and water 6-10 hours following application.2-4 Many considerations exist when using imiquimod. Some of these are listed in Box 1. The US FDA provides a full list of considerations.3
Mechanism of Action
Imiquimod is a Toll-like receptor agonist that induces the production of local cytokines from predominantly T helper (Th) 1-type cells, thus stimulating both acquired and cellular immunity, which is important for fighting virus-infected and tumor cells.5-7 Cytokines such as interferon (INF)-á, tumor necrosis factor (TNF)-á, interleukin (IL)-1, -6, -8, -10, and -12 stimulate tissue-specific apoptosis of virus-infected keratinocytes, thus leading to a viral load reduction of HPV types 6 and 11 with subsequent wart regression and normalization of keratinocyte proliferation.5,6,8 Regression of warts after treatment with imiquimod is strongly associated with evidence of tissue production of INF-á, -â, and -ã and TNF-á as well as a decrease in the presence of HPV DNA and in the expression of mRNA for both early and late viral proteins.9
In all the randomized controlled trials (RCTs) examined, topical imiquimod 5% cream showed an acceptable safety profile. Local skin reactions are associated with a local inflammatory reaction including itching, erythema, burning, irritation, tenderness, ulceration, erosion, and pain.10 In several studies, local erythema was the most common reaction.11-13 There were no differences in adverse systemic reactions or flu-like symptoms among treatment groups.10,12,13 The optimal dosing regimen is 3 times per week. With more frequent applications (up to 3 times daily), wart clearance does not improve significantly and is associated with an increase in local adverse events, such as erythema, vesicle formation, ulceration, and excoriation.14 Imiquimod 5% cream is effective for up to 16 weeks of treatment for external anogenital warts and is well-tolerated for up to 32 weeks.11 Imiquimod is contraindicated in individuals with a history of sensitivity reactions to any of its components and should be discontinued if hypersensitivity to any of its ingredients is noted. Overall, patient-applied imiquimod 5% cream is an effective treatment for external genital warts and has a favorable safety profile.
Efficacy and Recurrence
Several randomized controlled trials demonstrated that imiquimod 5% cream is an efficacious treatment for external anogenital warts when applied 3 times per week for up to 16 weeks. Complete clearance of warts occurred in up to 50% of patients treated with imiquimod 5% cream applied 3 times daily. At the end of 16 weeks, recurrence rates ranged from up to 19% after 3 months and 23% after 6 months.11 See Table 1 for comparisons. The recurrence rates of external genital warts were found to be similar at both 3- and 6-month follow-up, suggesting that after 3 months, the risk of developing recurrence is low.15
Beutner, Spruance et al.10
In a prospective, double-blind, placebo-controlled, clinical trial with 108 patients, imiquimod 5% cream was applied 3 times daily for up to 8 weeks. Complete wart clearance was achieved in 37% of the imiquimod-treated patients and 0% of the placebo group. Many patients experienced a partial response: an 80% or more reduction in baseline wart area was achieved in 62% of imiquimod-treated patients versus a 4% reduction in the placebo group. A 50% reduction in baseline wart area was noted in 76% of imiquimod-treated patients compared with 8% of the placebo group. For patients whose warts cleared completely, 19% experienced recurrences after a 10-week follow-up period. There were no differences in systemic reactions between treatment groups. Local inflammatory reactions were predominantly mild or moderate in severity and included itching (54%), erythema (33%), burning (31%), irritation (17%), tenderness (13%), ulceration (10%), erosion (10%), and pain (8%).
Garland et al.11
In an open-label phase IIIB trial consisting of 943 patients in 20 countries, imiquimod 5% cream applied 3 times per week was found to be 47.8% effective for overall complete clearance after 16 weeks of treatment. Recurrence rates at the end of 3- and 6-month follow-up were 8.8% and 23%, respectively. The sustained clearance rates (patients who cleared during treatment and remained clear at the end of the follow-up period) after 3 and 6 months were 41.6% and 33%, respectively. The study also found that a greater proportion of female patients (75.5%) experienced complete clearance than did male patients (56.9%). At least 1 adverse event was reported in 42% of patients; the majority of reactions were mild to moderate in severity. Local erythema was the most common local skin reaction, occurring in 67% of patients.
Edwards et al.12
Another RCT consisting of 311 patients was randomized to 3 arms: imiquimod 5% cream, imiquimod 1% cream, or vehicle 3 times per week for a maximum of 16 weeks. Complete clearance of lesions was achieved in 50% of patients who received the imiquimod 5% cream, 21% of those who received imiquimod 1% cream, and 11% of those treated with the placebo. After a 3-month follow-up, the study found a recurrence rate of at least 1 wart in 13% of patients who receive imiquimod 5% cream. The majority of patients experienced no or mild local inflammatory reactions, with local erythema being the most common. Local adverse reactions, which were moderate or severe in intensity after being treated with imiquimod 5% cream, included erythema (40%), erosion (10%), excoriation (7%), edema (2%), and scabbing (5%).
Beutner, Tyring et al.13
In another prospective, multicenter, double-blind, RCT with 279 patients, 94 patients used imiquimod 5% cream once-daily for up to 16 weeks. Complete wart clearance was achieved in 52% of patients treated with imiquimod 5% cream, but 19% of these patients had a recurrence at a 3-month follow-up. These results are similar to those obtained with 3 applications per week. When patients were treated with 5% imiquimod cream vs. vehicle, local adverse reactions included erythema (66% vs. 9%), excoriation (21% vs. 4%), erosion (32% vs. 1%), edema (18% vs. 1%), scabbing (18%), induration (5%), ulceration (10%), and vesicles (3%).
Support for Comparable Efficacy in Clearance Rates After 3 Weeks
Garland et al.11 found that a 1-month treatment course of imiquimod 5% cream applied 3 times weekly for women with external genital warts has comparable efficacy to a 4-month treatment with no statistically significant difference in complete clearance rates (i.e., 40% after 1 month and 51.6% after 4 months). The 1-month treatment had a lower incidence of local skin reactions, such as erythema, and no pain.18
Monotherapy Compared with Combination Therapy: Imiquimod + Surgery
Carrasco et al.19 showed that treatment with imiquimod 5% cream followed by excision of remaining warts resulted in a lower recurrence rate compared with surgery alone. This strategy represents a viable option for those with residual lesions and may provide long-term clearance of anogenital warts in patients for whom imiquimod monotherapy is insufficient.19
Patient-applied imiquimod 5% cream is a first-line topical treatment for anogenital warts that is both safe and efficacious, and yields complete and partial responses in the majority of patients. Various studies demonstrate complete clearance rates of up to 50% and partial responses manifest as a 50%-90% reduction in baseline wart area.12-14 Recurrence rates range up to 19% at 3 months and 23% at 6 months. More studies are needed to compare the efficacy of combination therapies vs. monotherapy vs. other treatment modalities. Longer follow-up is also needed to evaluate recurrence rates after monotherapy, as well as in combination with other treatments for anogenital warts.
In this issue:
All content ©2004-2017 SkinTherapyLetter® |
Last modified: Tuesday, 15-Dec-2015 15:40:01 MST